HomeCompareENTEF vs PFE

ENTEF vs PFE: Dividend Comparison 2026

ENTEF yields 8333.33% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ENTEF wins by $9167747390577058.00M in total portfolio value
10 years
ENTEF
ENTEF
● Live price
8333.33%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$9167747390577058.00M
Annual income
$8,956,326,004,308,616,000,000.00
Full ENTEF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — ENTEF vs PFE

📍 ENTEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodENTEFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ENTEF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ENTEF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ENTEF
Annual income on $10K today (after 15% tax)
$708,333.33/yr
After 10yr DRIP, annual income (after tax)
$7,612,877,103,662,324,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, ENTEF beats the other by $7,612,877,103,662,324,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ENTEF + PFE for your $10,000?

ENTEF: 50%PFE: 50%
100% PFE50/50100% ENTEF
Portfolio after 10yr
$4583873695288529.00M
Annual income
$4,478,163,002,154,308,000,000.00/yr
Blended yield
97.69%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

ENTEF
No analyst data
Altman Z
-17.7
Piotroski
1/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ENTEF buys
0
PFE buys
0
No recent congressional trades found for ENTEF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricENTEFPFE
Forward yield8333.33%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$9167747390577058.00M$49.6K
Annual income after 10y$8,956,326,004,308,616,000,000.00$26,258.71
Total dividends collected$9153631700876960.00M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ENTEF vs PFE ($10,000, DRIP)

YearENTEF PortfolioENTEF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$844,033$833,333.33$9,153$693.39+$834.9KENTEF
2$66,637,799$65,734,683.28$8,593$849.25+$66.63MENTEF
3$4,921,638,642$4,850,336,197.34$8,336$1,066.78+$4921.63MENTEF
4$340,059,751,219$334,793,597,872.29$8,437$1,384.80+$340059.74MENTEF
5$21,983,026,935,088$21,619,163,001,283.26$9,013$1,875.40+$21983026.93MENTEF
6$1,329,654,704,481,797$1,306,132,865,661,252.20$10,306$2,680.72+$1329654704.47MENTEF
7$75,256,486,591,502,860$73,833,756,057,707,330.00$12,820$4,101.38+$75256486591.49MENTEF
8$3,986,020,907,319,540,000$3,905,496,466,666,632,000.00$17,673$6,826.70+$3986020907319.52MENTEF
9$197,590,080,624,712,480,000$193,325,038,253,880,570,000.00$27,543$12,591.86+$197590080624712.44MENTEF
10$9,167,747,390,577,058,000,000$8,956,326,004,308,616,000,000.00$49,560$26,258.71+$9167747390577058.00MENTEF

ENTEF vs PFE: Complete Analysis 2026

ENTEFStock

ESE Entertainment Inc., an entertainment and technology company, focuses on gaming and esports in Europe and internationally. It consists of multiple assets and operators in the gaming and esports industries. The company's capabilities include physical infrastructure, broadcasting, global distribution for gaming and esports-related content, advertising, simulation racing business unit, and a growing esport team franchise, as well as K1CK Esports. It also engages in the infrastructure business that manages fan engagement for OTT and esports; and provision of gaming related infrastructure, technology, and support. In addition, the company offers out-sourced network services; operates telecommunications network; turnkey simulator packages; builds bespoke simulators; and Virtual Pitstop technology for video game developers, racing fans, and gamers to engage in motorsport related esports. It serves video game developers, publishers, and brands. The company was formerly known as Kepler Acquisition Corp. and changed its name to ESE Entertainment Inc. in August 12, 2020. ESE Entertainment Inc. was founded in 2019 and is headquartered in Vancouver, Canada.

Full ENTEF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this ENTEF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ENTEF vs SCHDENTEF vs JEPIENTEF vs OENTEF vs KOENTEF vs MAINENTEF vs JNJENTEF vs MRKENTEF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.